SecBot SecBot
144 ·Filed Jun 18, 2026

VCYT

VERACYTE, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001950047-26-006311
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing by a director for RSU vesting. No material trading signal, the sale is small relative to market cap and likely pre-planned. Monitor for actual execution, but no immediate action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$53.19
T+0 close · Jun 18, 2026 · via day close
Latest settled
−24.53%
T+60 · $40.14
Vs SPY
−26.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $53.19entry
  2. T+1 · 5mo ago +1.13%α +2.58% · $53.79
  3. T+5 · 5mo ago +13.72%α +15.79% · $60.49
  4. T+20 · 4mo ago +11.17%α +11.32% · $59.13
  5. T+60 · 2mo ago −24.53%α −26.28% · $40.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Karin Eastham filed a Form 144 notice of intent to sell 3,729 shares of Veracyte common stock, valued at approximately $191,260, from vested restricted stock units. This is a routine insider sale for tax or diversification purposes and carries no material signal about company fundamentals.

Key Facts

  • Insider: Director Karin Eastham
  • Shares to be sold: 3,729 shares of common stock
  • Estimated value: $191,260.41
  • Source of shares: Restricted stock units (vested)
  • Broker: Morgan Stanley Smith Barney LLC
  • Filing date: June 18, 2026

Financial Impact

Approximately $191,260 in planned insider sale, representing a negligible fraction of Veracyte's $4.1B market cap.

dilution

Risk Factors

  • Insider may not execute the sale; Form 144 is an intent notice only.
  • Additional insider sales could emerge if other directors or officers file similar notices.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
83% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006311
Document: 0001950047-26-006311-index.html0001950047-26-006311
Document: 0001950047-26-006311.txt0001950047-26-006311

Track record

22 reports on VCYT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
  2. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
  4. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
  5. Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  6. Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  7. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  8. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  9. Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
  10. Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (11h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026